PRI-002

Small molecule

Partialdesign only

Evidence outlook · topline reported

PRImus-AD (NCT06182085) · Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset

The sponsor reported topline results on 2026-11-17 (Phase 2 PRImus-AD topline: CDR-SB efficacy endpoint not met; safety endpoint met). The tier describes the lead study's design. The announcement is listed under Regulatory events.

PRImus-AD (NCT06182085): The study randomized 304 participants to two PRI-002 dose groups or placebo and used quadruple masking of participants, caregivers, investigators, and outcome assessors. Its primary efficacy measure was the clinical CDR-SB outcome, but whether the primary comparison was met cannot be determined because results are not available.

Source for the program status

Company guidance: topline data expected in 2027 (Priavoid GmbH, 17 Nov 2026). “The topline findings, presented in an oral presentation at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, support PRI-002’s further clinical development as a potentially disease-modifying oral treatment for Alzheimer's disease, with the full dataset expected to be presented in 2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Alzheimer's Disease
Phase 1 (3)
Alzheimer's Disease
NCT04711486 · Charite University, Berlin, Germany
2020-12-08 – 2022-01-13 · Mild Cognitive Impairment Due to Alzheimer's Disease
What this study did
NCT03955380 · Prof. Dr. Dieter Willbold
2018-12-12 – 2019-04-03 · Alzheimer Dementia, Alzheimer Disease
What this study did
NCT03944460 · Prof. Dr. Dieter Willbold
2018-04-09 – 2018-07-27 · Alzheimer Dementia, Alzheimer Disease
What this study did

Competitive landscape

This drug's own stage for Alzheimer's Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PRI-002: this drugPhase 2Small moleculeAmyloid-beta-42 oligomerizationPartial signalNo reviewed efficacy summary in this indication
Benzgalantamine (Zunveyl)ApprovedSmall moleculeAcetylcholinesterase/nicotinic receptor (prodrug)not yet gradedNo reviewed efficacy summary in this indication
Donanemab (Kisunla)ApprovedMonoclonal antibodyAmyloid-beta (monoclonal antibody)Partial signal
NCT05108922: Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab (6 Months): Donanemab 37.9% (95% CI 26.2 to 49.6) vs Aducanumab 1.6% (95% CI 0 to 4.6)
Donepezil (Aricept)ApprovedSmall moleculeAcetylcholinesterasePartial signal
NCT00630851: Primary endpoint, SIB change at 6 months: mean difference 5.9 points vs placebo, statistically significant (ARICEPT label, Swedish 6-month study, 248 randomized).
Lecanemab (Leqembi)ApprovedMonoclonal antibodyAmyloid-beta (monoclonal antibody)Partial signal
NCT01767311: ADCOMS change from baseline at Month 12 (lower = less decline): lecanemab 10 mg/kg biweekly 0.077 and 10 mg/kg monthly 0.084 vs placebo 0.113; lower doses did not separate: 2.5 mg/kg biweekly 0.134, 5 mg/kg monthly 0.119, 5 mg/kg biweekly 0.116. missed
AR1001Phase 3Small moleculePDE5Partial signal
NCT03625622: Primary (ADAS-Cog-13 at Week 26): no significant differences between treatment groups in the overall population; post-hoc monotherapy subgroup on AR1001 30 mg improved 4.019 points (p=0.012). missed
BezisterimPhase 3Small moleculeERK/NF-kB inflammatoryPartial signalNo reviewed efficacy summary in this indication
Brexpiprazole (Rexulti)Phase 3Small moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT01862640: Change in CMAI Total score from baseline to Week 12 vs placebo (Study 1 = NCT01862640): brexpiprazole 2mg/day adjusted mean difference -3.77 (95% CI -7.38 to -0.17), p=0.040; brexpiprazole 1mg/day 0.23 (95% CI -3.40 to 3.86), p=0.90
NCT03620981: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. (Baseline and 10 weeks first dose, on average 10 weeks): Brexpiprazole 1 mg -11.7 units on a scale (Standard Error 1.2) | Brexpiprazole 2 mg -15.2 units on a scale (Standard Error 1.05) vs Placebo -8 units on a scale (Standard Error 1.03)
BuntanetapPhase 3Small moleculeAPP/tau/alpha-synuclein/TDP-43 (translation)Partial signal
NCT05686044: ADAS-Cog11 change at Week 12: -2.32 placebo vs -1.34 (7.5 mg), -3.01 (15 mg), and -2.24 (30 mg) buntanetap/Posiphen; ADCS-CGIC at Week 12: 3.58 placebo vs 3.96 (7.5 mg), 3.61 (15 mg), and 3.83 (30 mg).
Hydromethylthionine MesylatePhase 3Small moleculeTau aggregation; AcetylcholinePartial signal
NCT03446001: Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (16 mg/Day vs Control) (52 weeks): TRx0237 16 mg/Day 1.34 score on a scale (95% CI 0.32 to 2.36) vs Control 1.71 score on a scale (95% CI 0.69 to 2.73)
NCT01689233: As-randomized primary comparison (100 mg vs 4 mg twice daily, the trial's pre-specified design): no significant difference on primary or secondary outcomes. Post-hoc modified-primary-outcome monotherapy cohort analysis: ADAS-cog effect size -3.14 (95% CI -5.32 to -0.97, p=0.0047) for 100 mg monotherapy (n=76) vs 4 mg as-randomized (n=388); -4.22 (95% CI -6.19 to -2.24, p<0.0001) for 4 mg monotherapy (n=79) vs 4 mg add-on (n=309)
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01872598: Co-primary endpoints at week 24, masitinib 4.5 mg/kg/day vs placebo, each tested at 2.5%: ADAS-cog difference -2.15 (97.5% CI -3.48 to -0.81), p<0.001 (met); ADCS-ADL difference +1.82 (97.5% CI -0.15 to 3.79), p=0.038 (not met at the 2.5% level)
MasupirdinePhase 3Small moleculeSerotonin 5-HT6 receptorPartial signal
NCT02580305: ADAS-Cog 11 change from baseline at Week 26: placebo +2.6 (SE 0.5); masupirdine 50 mg +2.0 (SE 0.5), difference vs placebo -0.5 (95% CI -1.8, 0.7; P=.41); masupirdine 100 mg +2.5 (SE 0.5), difference vs placebo -0.1 (95% CI -1.4, 1.2; P=.90) missed
MLC901 (NeuroAiD II)Phase 3BotanicalTraditional Chinese medicine (multi-component)not yet gradedNo reviewed efficacy summary in this indication
RemlifanserinPhase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
RemternetugPhase 3Monoclonal antibodyAmyloid-beta (monoclonal antibody)Partial signalNo reviewed efficacy summary in this indication
Sodium OligomannatePhase 3Small moleculeGut microbiome / neuroinflammationReliable signal
NCT02293915: Change in ADAS-cog12 from baseline to Week 36 (GV-971 minus placebo): -2.15 points (95% CI -3.07 to -1.23; p<0.0001; Cohen's d 0.53), favoring GV-971
TertomotidePhase 3PeptideTelomerase (hTERT)Partial signal
NCT05189210: 52주 차 ADAS-cog11의 최소제곱평균값 변화량은 GV1001 0.56mg과 1.12mg 투약군에서 각각 4.14점, 4.31점으로 위약군 4.30점 (LS-mean change in ADAS-cog11 at week 52: GV1001 0.56 mg 4.14 points, 1.12 mg 4.31 points, placebo 4.30 points; not statistically significant) missed
TricaprilinPhase 3Small moleculeKetone-body metabolismPartial signal
NCT01741194: Change from baseline at 26 weeks, ADAS-Cog11 (APOE4 non-carriers): placebo (n=138) 0.0 vs AC-1204/tricaprilin (n=137) 0.6; LS mean difference -0.761, p=0.2458 (not significant) missed
TrontinemabPhase 3Multispecific antibodyAmyloid-beta (monoclonal antibody)not yet gradedNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
AGB101Phase 2/3Small moleculeSynaptic vesicle glycoprotein 2A (SV2A), low-dosePartial signal
NCT03486938: CDR-SB difference vs placebo -0.10 (95% CI -0.85 to 0.58), not significant missed
BlarcamesinePhase 2/3Small moleculeSigma-1 receptor / muscarinic receptor (dual)Partial signal
NCT03790709: Co-primary endpoints at 48 weeks: ADAS-Cog13 difference vs placebo -2.027 (95% CI -3.522 to -0.533; P = 0.008); ADCS-ADL difference 0.775 (95% CI -0.874 to 2.423; P = 0.357, not significant). missed
DeramciclanePhase 2/3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
DeraphanPhase 2/3Small moleculeNMDA receptor / 5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
Emestedastat (Xanamem)Phase 2/3Small molecule11-beta-HSD1Partial signal
NCT02727699: ADAS-Cog v14 (Baseline, Week 12): Xanamem™ -1.5 units on a scale (Standard Deviation 6.47) vs Placebo -0.7 units on a scale (Standard Deviation 6.65)
EtalanetugPhase 2/3Monoclonal antibodyTau (monoclonal antibody)Weak signalFeatured results are safety only in this race
NivegacetorPhase 2/3UndisclosedGamma-secretase (modulator)not yet gradedNo reviewed efficacy summary in this indication
PM012Phase 2/3BotanicalTraditional Chinese medicine (multi-component)Partial signalNo reviewed efficacy summary in this indication
T3D-959Phase 2/3Small moleculePPAR delta/gammaPartial signalNo reviewed efficacy summary in this indication
50561Phase 2Small moleculeRAC1Partial signalNo reviewed efficacy summary in this indication
AADvac1Phase 2VaccineTauWeak signalFeatured results are safety only in this race
ABvac40Phase 2VaccineAmyloid-beta (Aβx-40)Partial signalFeatured results are non-efficacy and safety only in this race
ACI-35.030Phase 2VaccineTauPartial signalFeatured results are safety only in this race
AD04Phase 2VaccineAluminium hydroxide (Alhydrogel)not yet gradedNo reviewed efficacy summary in this indication
AstroStemPhase 2Cell therapyMesenchymal stem cell therapyWeak signal
NCT03117738: ADAS-Cog change at Week 30: 5.9 (SD 6.8) AstroStem vs 3.0 (SD 5.4) placebo; n=7 vs 7.
AV-1959RPhase 2VaccineAmyloid-betaWeak signalFeatured results are safety only in this race
BepranemabPhase 2Monoclonal antibodyTau (monoclonal antibody)Partial signal
NCT04867616: Primary endpoint, change in CDR-SB total score at Week 80: no benefit of low- or high-dose bepranemab over placebo in the overall study population (per UCB; no figures or p-value released). Key secondary outcomes favoured bepranemab: tau accumulation slowed by 33% to 58% and ADAS-Cog14 decline by 21% to 25% vs placebo. missed
Betovumeline / Fesoterodine (ML-007C-MA)Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)not yet gradedNo reviewed efficacy summary in this indication
BEY2153Phase 2Small moleculeAPP/tau (translation)Partial signalNo reviewed efficacy summary in this indication
CerebrolysinPhase 2PeptidePorcine brain-derived neuropeptide mixture (multi-target)Partial signal
NCT00911807: Week 28 ADAS-COG+ change: -2.348 Cerebrolysin + donepezil, -1.711 Cerebrolysin, and -1.246 donepezil; overall p=0.6348. Cerebrolysin + donepezil vs donepezil: mean difference -1.080 (95% CI -3.324 to 1.163; p=0.3434). missed
DeulumateperonePhase 2Small moleculeSerotonin 5-HT2A / dopamine D1-D2 receptornot yet gradedNo reviewed efficacy summary in this indication
DiranersenPhase 2RNA / oligonucleotideMAPT mRNA (RNAi/ASO)Weak signal
NCT05399888: Diranersen/BIIB080 (NCT05399888), Phase 2 CELIA study: primary endpoint (dose-response on CDR-SB change from baseline at Week 76) not met. missed
Edaravone (TTYP01)Phase 2Small moleculeoxidative stressnot yet gradedNo reviewed efficacy summary in this indication
EnrupatinibPhase 2Small moleculeCSF-1Rnot yet gradedNo reviewed efficacy summary in this indication
HT-4253Phase 2Small moleculeLRRK2not yet gradedNo reviewed efficacy summary in this indication
Laromestrocel (Lomecel-B)Phase 2Cell therapyMesenchymal stem cell therapyWeak signalFeatured results are safety only in this race
Lemborexant (Dayvigo)Phase 2Small moleculeOrexin receptor (repositioned)Partial signal
NCT03001557: 4-week actigraphy endpoints vs placebo: L5 (restlessness measure) significantly decreased at 2.5mg, 5mg and 15mg doses (all p<0.05); relative amplitude significantly improved at 5mg and 15mg (both p<0.05); mean duration of sleep bouts significantly improved at 5mg (p<0.01) and 15mg (p=0.002).
LeronlimabPhase 2Monoclonal antibodyCCR5 co-receptornot yet gradedNo reviewed efficacy summary in this indication
LHP588Phase 2Small moleculeGingipainnot yet gradedNo reviewed efficacy summary in this indication
Lifonebart (VHB937)Phase 2Monoclonal antibodyTREM2not yet gradedNo reviewed efficacy summary in this indication
MivelsiranPhase 2RNA / oligonucleotideAPP mRNA (RNAi)not yet gradedNo reviewed efficacy summary in this indication
MK-2214Phase 2Monoclonal antibodyPhospho-tau (pSer413)Partial signalFeatured results are safety only in this race
MoponetugPhase 2Monoclonal antibodyTau (monoclonal antibody)not yet gradedNo reviewed efficacy summary in this indication
NTRX-07Phase 2Small moleculeCB2 receptorWeak signalFeatured results are safety only in this race
ONO-2020Phase 2Small moleculeEpigenetic regulation (target undisclosed)not yet gradedNo reviewed efficacy summary in this indication
PegipanerminPhase 2Biologic (subtype unspecified)Soluble TNF (selective)Partial signal
NCT05318976: Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) (24 Weeks): 1.0 mg/kg XPro1595 0.05 z-score (Standard Error 0.04) vs 1.0 mg/kg Placebo 0.07 z-score (Standard Error 0.05) missed
RB-ADSCPhase 2Cell therapyMesenchymal stem cell therapynot yet gradedNo reviewed efficacy summary in this indication
RO7269162Phase 2Small moleculeGamma-secretasenot yet gradedNo reviewed efficacy summary in this indication
SAR448851Phase 2Small moleculeTREM2Weak signalFeatured results are safety only in this race
SeltorexantPhase 2Small moleculeOrexin-2 receptor (OX2R)not yet gradedNo reviewed efficacy summary in this indication
SHR-1707Phase 2Monoclonal antibodyAmyloid-beta (monoclonal antibody)Partial signalNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 62 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026Topline resultPhase 2 PRImus-AD topline: CDR-SB efficacy endpoint not met; safety endpoint met